Advertisement

Advances in Therapy

, Volume 35, Issue 2, pp 210–217 | Cite as

Single-Dose Comparative Pharmacokinetics of Two Formulations of Lenalidomide 25 mg in Healthy Subjects: A Randomized Crossover Study

  • SeungHwan Lee
  • Jun Gi Hwang
  • Sang Yeob Park
  • Hye Jung Lim
  • Sa-Won Lee
  • Min-Hyo Seo
  • JaeWoo Kim
  • Jang Hee HongEmail author
Original Research

Abstract

Background

Lenalidomide is used for the treatment of multiple myeloma in combination with dexamethasone. The purpose of this study was to compare the pharmacokinetics (PKs) and assess the bioequivalence of two formulations of lenalidomide 25 mg: Lenalid® 25 mg tablet (test formulation) and Revlimid® 25 mg capsule (reference formulation).

Methods

A randomized, single-dose, two-treatment, two-period, two-sequence crossover study was conducted in 42 healthy subjects. All subjects were randomly assigned to one of the two sequences, and they received a single dose of test or reference formulation in the first period and the alternative formulation during the next period under fasting conditions. Serial blood samples for PK evaluation were collected up to 24 h post-dose and the PK parameters were estimated by non-compartmental methods. Throughout the study, tolerability was assessed on the basis of adverse events, vital signs, and clinical laboratory tests.

Results

The test formulation showed similar PK profiles to those of the reference formulation. The geometric mean ratio and 90% confidence interval (CI) of the test formulation to the reference formulation for maximum plasma concentration (Cmax) was 0.9995 (0.9250–1.0799) and the corresponding value for the area under the concentration–time curve from time zero to time of last quantifiable concentration (AUCt) was 0.9648 (0.9451–0.9850). Both CIs were within the conventional bioequivalence range of 0.8–1.25. The tolerability profile was not significantly different between the two formulations.

Conclusion

This study found that the PKs of the two formulations of lenalidomide 25 mg were similar and the test formulation met the regulatory criteria for assuming bioequivalence with the reference formulation.

Funding

Samyang Biopharmaceutical Corp.

Keywords

Bioequivalence Lenalidomide Pharmacokinetics 

Notes

Acknowledgments

Funding

This study and the article processing fee in this journal were funded by the sponsor Samyang Biopharmaceutical Corp., Seongnam-si, Gyeonggi-do, Korea. Also this study was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &Welfare, Republic of Korea (grant number: HI14C1063) and a research fund of Chungnam National University and supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A1B04033515). All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Sang Yeob Park is an employee of Samyang Biopharmaceuticals Corp. Hye Jung Lim is an employee of Samyang Biopharmaceuticals Corp. Sa-Won Lee is an employee of Samyang Biopharmaceuticals Corp. Min-Hyo Seo is an employee of Samyang Biopharmaceuticals Corp. SeungHwan Lee, Jun Gi Hwang, JaeWoo Kim, and Jang Hee Hong have nothing to disclose.

Compliance with Ethics Guidelines

This study was conducted in accordance with the ethical principles of the 1964 Declaration of Helsinki and its later amendments, as well as the rules of Korean Good Clinical Practice. All subjects provided written informed consent after receiving a detailed explanation about the study prior to any study related procedures.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. 1.
    Celgene Corporation. REVLIMID [lenalidomide] capsules, for oral use. Prescribing Information. 2017; https://media.celgene.com/content/uploads/revlimid-pi.pdf.
  2. 2.
    Zeldis JB, Knight R, Hussein M, Chopra R, Muller G. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann N Y Acad Sci. 2011;1222:76–82.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54:683–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Blumel S, Broadway-Duren J. Approaches to managing safety with lenalidomide in hematologic malignancies. J Adv Pract Oncol. 2014;5:269–79.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Chen N, Kasserra C, Reyes J, Liu L, Lau H. Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. Cancer Chemother Pharmacol. 2012;70:717–25.CrossRefPubMedGoogle Scholar
  6. 6.
    Chen N, Wen L, Lau H, Surapaneni S, Kumar G. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol. 2012;69:789–97.CrossRefPubMedGoogle Scholar
  7. 7.
    Chen N, Zhou S, Palmisano M. Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet. 2017;56:139–52.CrossRefPubMedGoogle Scholar
  8. 8.
    US Food and Drug Administration. Draft Guidance on Lenalidomide. 2013; https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm326798.pdf.
  9. 9.
    European Medicines Agency. Lenalidomide hard gelatine capsules 2.5, 5, 7.5, 10, 15 and 25 mg product-specific bioequivalence guidance: Draft. 2015; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500195125.pdf.
  10. 10.
    Chen N, Ye Y, Liu L, et al. Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men. Basic Clin Pharmacol Toxicol. 2013;113:179–86.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical Pharmacology and TherapeuticsSeoul National University Hospital and College of MedicineSeoulRepublic of Korea
  2. 2.Samyang Biopharmaceuticals CorpGyeonggi-doRepublic of Korea
  3. 3.Department of PharmacologyChungnam National University College of Medicine and HospitalDaejeonRepublic of Korea

Personalised recommendations